



Novel Chemical Spray That Lights Up Tumors

Singapore, 13 March 2026 – SGX Catalist-listed Abundance International Limited (the “Company”) today announced that its wholly owned subsidiary, Abundance Specialty Chemicals Pte Ltd (“ASC”), has signed a licensing agreement (the “Licensing Agreement”) with Molecular Targeting Technologies, Inc. (“MTTI”).

MTTI has secured a worldwide exclusive license from Cornell University for CypH-11, a novel agent designed to detect viable tumor cells. When formulated as an intraoperative spray, CypH-11 has the potential to enable surgeons to clearly distinguish cancerous tissue from surrounding healthy tissue in real time during surgery. This capability may support more precise tumor resection and help reduce the risk of relapse associated with residual cancer cells.

Pursuant to the License Agreement, ASC will acquire the exclusive license to CypH-11 in certain countries within the Asia-Pacific region (the “Territories”). This license will enable ASC to develop and commercialize the technology, including the potential formulation of CypH-11 as a specialty chemical spray for use during cancer-related surgical procedures.

Dr. Brian Gray, Senior Vice President of Product Development at MTTI said, “Our sprayable, fast-acting, sensitive and tumor specific fluorescent agent CypH-11 makes ovarian cancer tumors glow under near infrared light during surgery. It allows the surgeon see more cancerous tissue, making cancer debulking more precise, safer, improving outcomes and reducing recurrence.”

Dr. Chris Pak, President & CEO of MTTI, stated, “This spray technology is designed to respond to the acidic tumor microenvironment. In preclinical models, it delineated tumors as small as 1 mm within minutes of application, without the need for washing. We are actively exploring its potential use in ovarian, oral, skin, and esophageal cancers, as well as glioblastoma multiforme.”

Managing Director of the Company, Mr. Sam Kok Yin, said, “We are excited about this new addition to our portfolio of chemical products. We have already identified several potential applications for this chemical spray in the medical field. Although the technology is still at an early stage and there remains some way to go before commercialization, the market potential is substantial. We will dedicate our utmost efforts to developing this product in the Territories and may, where appropriate, pursue collaborations with strategic partners or grant sublicenses if doing so would be beneficial.”

Molecular Targeting Technologies, Inc. MTTI is a private, clinical-stage biotechnology company developing targeted radiotherapeutics (TRT). MTTI is committed to creating value by translating innovative TRT technologies into therapies that improve human health. For more information, please visit www.mtarget.com. Please contact: Chris Pak. cpak@mtarget.com